Market Cap 6.31B
Revenue (ttm) 806.78M
Net Income (ttm) -363.30M
EPS (ttm) N/A
PE Ratio 8.55
Forward PE 9.39
Profit Margin -45.03%
Debt to Equity Ratio -15.20
Volume 525,500
Avg Vol 1,595,426
Day's Range N/A - N/A
Shares Out 80.29M
Stochastic %K 74%
Beta 0.47
Analysts Sell
Price Target $81.86

Company Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spina...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 222 7000
Fax: 908 222 7231
Address:
500 Warren Corporate Center Drive, Warren, United States
GorgonGains
GorgonGains Dec. 27 at 6:02 AM
$PTCT Expectations are resetting toward sustainable results, not one‑off wins. Governance alignment can reduce perceived uncertainty. Credible progress tends to compress risk premiums. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 11:40 AM
$PTCT Current Stock Price: $78.29 Contracts to trade: $80 PTCT Jan 16 2026 Call Entry: $3.33 Exit: $5.21 ROI: 56% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JourneyJunction
JourneyJunction Dec. 26 at 5:34 AM
$PTCT Investors are watching management behavior more closely than guidance language. Cash generation will determine how self-sustaining growth becomes. Improved transparency could compress valuation discounts. Patience is sensible — but only if matched by progress.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:58 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT closed at $78.37, showing stability above the 30-day moving average (MA30) of $77.4. The RSI at 51.73 indicates a neutral momentum, suggesting potential for upward movement. The recent 60-day high of $87.5 offers a resistance level to target. Directional Bias: With the price above MA30 and MA50 (73.9), there is a bullish bias. The range between the 60-day high and low (60.79) indicates volatility, providing opportunities for profit. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close to confirm momentum) - Stop Loss: $75.00 (below MA30 to limit risk) - Take Profit Targets: 1. $83.00 (6% gain) 2. $87.00 (11% gain) 3. $91.50 (17% gain) This plan aims for a minimum of 17% ROI on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JasonCO
JasonCO Dec. 19 at 5:29 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:54 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $74.59, significantly below its 60-day high of $87.5 and near its 60-day low of $57.74. The RSI at 23.04 indicates the stock is oversold, suggesting a potential reversal. Directional Bias: Given the low RSI and proximity to the 60-day low, we anticipate a bullish reversal. The 30-day moving average (MA30) at $76.63 serves as resistance, while the 50-day moving average (MA50) at $72.91 provides support. Trade Plan: - Suggested Entry: $74.59 - Stop Loss: $71.00 (approx. 4% risk) - Take Profit Targets: 1. Target 1: $78.00 (4.3% gain) 2. Target 2: $82.00 (9.8% gain) 3. Target 3: $87.00 (16.6% gain) This plan offers a risk-reward ratio that aligns with our 17% ROI goal on the third target. Monitor closely for price action around the MA30. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:39 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $75.42, showing a bearish sentiment with an RSI of 34.28, indicating oversold conditions. The stock is below both the 30-day moving average (MA30) of 76.3 and the 50-day moving average (MA50) of 72.49, suggesting a potential reversal opportunity. Directional Bias: Given the RSI and the proximity to the 60-day low of 57.74, we anticipate a bullish reversal. The ATR of 3.18 indicates moderate volatility, providing room for price movement. Trade Plan: - Suggested Entry: $75.50 - Stop Loss: $71.50 (3.96% below entry) - Take Profit Targets: 1. TP1: $80.00 (5.8% gain) 2. TP2: $85.00 (12.6% gain) 3. TP3: $88.00 (16.6% gain) With a focus on a potential upside toward the 60-day high of 87.5, this trade plan offers a solid risk-reward ratio. Monitor closely for any changes in market conditions. https://privateprofiteers.com
0 · Reply
StockConsultant
StockConsultant Dec. 16 at 2:25 PM
$PTCT PTC Therapeutics stock watch, pullback to 75.65 support area with high trade quality
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 15 at 8:45 PM
This small-cap stock just saw the largest superinvestor inflow. Ever. Buyers in Q3: • Jefferies Group: $82M (New) • Steven Cohen: $63M (New) • Ken Griffin: $42M (+88%) • Ray Dalio: $1M (New) $PTCT
0 · Reply
Dr_Stoxx
Dr_Stoxx Dec. 15 at 4:10 PM
$PTCT bio looks good.
0 · Reply
Latest News on PTCT
PTC Therapeutics to Host R&D Day

Nov 20, 2025, 8:00 AM EST - 5 weeks ago

PTC Therapeutics to Host R&D Day


PTC Therapeutics to Participate at Upcoming Investor Conferences

Oct 31, 2025, 8:00 AM EDT - 2 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences


PTC Therapeutics Stock Is Stuck In A Multi-Year Slump

Aug 21, 2025, 10:00 AM EDT - 4 months ago

PTC Therapeutics Stock Is Stuck In A Multi-Year Slump


PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:19 PM EDT - 5 months ago

PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript


These Analysts Increase Their Forecasts On PTC Therapeutics

Jul 29, 2025, 11:23 AM EDT - 5 months ago

These Analysts Increase Their Forecasts On PTC Therapeutics


US FDA approves PTC Therapeutics' metabolic disorder drug

Jul 28, 2025, 4:25 PM EDT - 5 months ago

US FDA approves PTC Therapeutics' metabolic disorder drug


GorgonGains
GorgonGains Dec. 27 at 6:02 AM
$PTCT Expectations are resetting toward sustainable results, not one‑off wins. Governance alignment can reduce perceived uncertainty. Credible progress tends to compress risk premiums. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 11:40 AM
$PTCT Current Stock Price: $78.29 Contracts to trade: $80 PTCT Jan 16 2026 Call Entry: $3.33 Exit: $5.21 ROI: 56% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JourneyJunction
JourneyJunction Dec. 26 at 5:34 AM
$PTCT Investors are watching management behavior more closely than guidance language. Cash generation will determine how self-sustaining growth becomes. Improved transparency could compress valuation discounts. Patience is sensible — but only if matched by progress.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:58 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT closed at $78.37, showing stability above the 30-day moving average (MA30) of $77.4. The RSI at 51.73 indicates a neutral momentum, suggesting potential for upward movement. The recent 60-day high of $87.5 offers a resistance level to target. Directional Bias: With the price above MA30 and MA50 (73.9), there is a bullish bias. The range between the 60-day high and low (60.79) indicates volatility, providing opportunities for profit. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close to confirm momentum) - Stop Loss: $75.00 (below MA30 to limit risk) - Take Profit Targets: 1. $83.00 (6% gain) 2. $87.00 (11% gain) 3. $91.50 (17% gain) This plan aims for a minimum of 17% ROI on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JasonCO
JasonCO Dec. 19 at 5:29 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:54 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $74.59, significantly below its 60-day high of $87.5 and near its 60-day low of $57.74. The RSI at 23.04 indicates the stock is oversold, suggesting a potential reversal. Directional Bias: Given the low RSI and proximity to the 60-day low, we anticipate a bullish reversal. The 30-day moving average (MA30) at $76.63 serves as resistance, while the 50-day moving average (MA50) at $72.91 provides support. Trade Plan: - Suggested Entry: $74.59 - Stop Loss: $71.00 (approx. 4% risk) - Take Profit Targets: 1. Target 1: $78.00 (4.3% gain) 2. Target 2: $82.00 (9.8% gain) 3. Target 3: $87.00 (16.6% gain) This plan offers a risk-reward ratio that aligns with our 17% ROI goal on the third target. Monitor closely for price action around the MA30. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:39 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $75.42, showing a bearish sentiment with an RSI of 34.28, indicating oversold conditions. The stock is below both the 30-day moving average (MA30) of 76.3 and the 50-day moving average (MA50) of 72.49, suggesting a potential reversal opportunity. Directional Bias: Given the RSI and the proximity to the 60-day low of 57.74, we anticipate a bullish reversal. The ATR of 3.18 indicates moderate volatility, providing room for price movement. Trade Plan: - Suggested Entry: $75.50 - Stop Loss: $71.50 (3.96% below entry) - Take Profit Targets: 1. TP1: $80.00 (5.8% gain) 2. TP2: $85.00 (12.6% gain) 3. TP3: $88.00 (16.6% gain) With a focus on a potential upside toward the 60-day high of 87.5, this trade plan offers a solid risk-reward ratio. Monitor closely for any changes in market conditions. https://privateprofiteers.com
0 · Reply
StockConsultant
StockConsultant Dec. 16 at 2:25 PM
$PTCT PTC Therapeutics stock watch, pullback to 75.65 support area with high trade quality
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 15 at 8:45 PM
This small-cap stock just saw the largest superinvestor inflow. Ever. Buyers in Q3: • Jefferies Group: $82M (New) • Steven Cohen: $63M (New) • Ken Griffin: $42M (+88%) • Ray Dalio: $1M (New) $PTCT
0 · Reply
Dr_Stoxx
Dr_Stoxx Dec. 15 at 4:10 PM
$PTCT bio looks good.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:12 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $75.64, showing a neutral RSI of 44.74, indicating no immediate overbought or oversold conditions. The stock is near its 30-day moving average (MA30) of $75.78, suggesting potential resistance, while the 50-day moving average (MA50) of $72.06 indicates support. Directional Bias: Given the current price is close to the MA30, we anticipate a possible bounce back towards the 60-day high of $87.5. The range between the 60D high and low (57.74) provides a significant upside potential. Trade Plan: - Suggested Entry: $75.50 - Stop Loss: $72.00 (approx. 4% risk) - Take Profit Targets: 1. $80.00 (6.5% ROI) 2. $85.00 (12.3% ROI) 3. $88.50 (17.0% ROI) This trade plan allows for a favorable risk-reward ratio with a clear exit strategy. Monitor closely for price action around the MA30. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:06 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $75.17, with an RSI of 47.73, indicating a neutral momentum. The stock is positioned between the 60D high of $87.5 and the low of $57.74, suggesting potential for upward movement. The MA30 at $75.52 is slightly above the current price, while the MA50 at $71.8 provides support. Directional Bias: The neutral RSI indicates a potential for upward movement, especially as the price approaches the MA30. The proximity to the 60D high also suggests that a breakout could occur. Trade Plan: - Suggested Entry: $75.50 - Stop Loss: $71.00 (below MA50 for protection) - Take Profit Targets: 1. $80.00 (6.6% ROI) 2. $85.00 (12.9% ROI) 3. $88.00 (17.0% ROI) This trade plan capitalizes on the potential for upward movement while maintaining a solid risk management strategy. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 10 at 1:15 PM
Piper Sandler⬆️ $CAPR's PT to $45 from $20 and reiterated at an Overweight rating. $EWTX $PTCT $SRPT $DYN Piper Sandler in its note to investors: Last Wednesday, the Phase III HOPE-3 (N=106) trial met the primary endpoint showing a significant 1.2 point absolute difference from placebo in the Performance of the Upper Limb 2.0 (PUL 2.0, p=0.029). Deramiocel also met the key cardiac endpoint showing an absolute 2.4% improvement in LVEF, representing a 91% slowing of decline vs. placebo. (p=0.041) Capricor will submit HOPE-3 data as a response to the FDA's CRL under the current BLA for deramiocel in DMD cardiomyopathy by YE:25. We anticipate a Type II 6- month review resulting in potential deramiocel approval by mid'26. Capricor is eligible for an $80 million approval milestone from partner Nippon Shinyaku and could receive a valuable Priority Review Voucher (PRV). We reiterate our Overweight rating and are increasing our 12-month price target to $45 from $20 based on positive HOPE-3 data.
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:09 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $73.47, within a 60-day high of $87.5 and a low of $57.74. The RSI at 44.39 indicates a neutral position, suggesting potential for upward movement. The stock is below the 30-day moving average (MA30) of 75.04 but above the 50-day moving average (MA50) of 71.29, indicating mixed short-term momentum. Directional Bias: The proximity to the MA50 and the neutral RSI suggests a potential bullish reversal. The stock is currently undervalued relative to its recent high, providing a favorable risk-reward scenario. Trade Plan: - Suggested Entry: $73.50 - Stop Loss: $70.00 (3.4% risk) - Take Profit Targets: - Target 1: $78.00 (6.8% gain) - Target 2: $82.00 (11.6% gain) - Target 3: $86.00 (17% gain) This plan offers a clear path to capitalize on potential upward momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:57 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $76.9, positioned near the midpoint of its 60-day high of $87.5 and low of $57.74. The RSI of 52.47 indicates neutral momentum, suggesting potential for upward movement. The stock is above both the 30-day MA of $74.83 and the 50-day MA of $71.03, indicating bullish sentiment. Directional Bias: Given the current price relative to the moving averages and the RSI, we anticipate a bullish trend, especially as it approaches the higher end of the recent range. Trade Plan: - Suggested Entry: $77.00 - Stop Loss: $73.00 (4% below entry) - Take Profit Targets: - Target 1: $80.00 (3.9% gain) - Target 2: $84.00 (9.1% gain) - Target 3: $90.00 (16.9% gain) This plan provides a solid risk-reward ratio with a potential ROI of over 17% on the third target. Monitor closely for adjustments based on market conditions. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 8 at 1:41 PM
Raymond James⬆️ $DYN's PT to $40 from $35 and reiterated at a SB, $CAPR $EWTX $PTCT $SRPT Raymond James said: This morning, Dyne announced positive topline data from the registrational expansion cohort (REC) of the Ph2 DELIVER study of z-rostudirsen (formerly DYNE-251) in Duchenne muscular dystrophy amenable to exon 51 skipping (DMD51); presentation here. These results de-risk FDA accelerated approval, in our view, and also provide incremental de-risking for an eventual confirmatory trial. We raise our price target to $40 and reiterate our Strong Buy rating.
0 · Reply
Quantumup
Quantumup Dec. 8 at 12:39 PM
Oppenheimer⬆️the PT on $CAPR to $54 from $22 and reiterated at an Outperform rating. $EWTX $DYN $PTCT $SRPT Oppenheimer said: We raise our PT to $54 (from $22) following deramiocel's broadly positive Phase 3 results (which we anticipate will drive a mid-2026 full FDA approval for those ≥10 years of age with Duchenne muscular dystrophy) and CAPR's financing (which we expect to enable the company to achieve profitability by 2028). We believe deramiocel's clinical profile stands second to none relative to approved DMD therapeutics, and our projected 2031 sales of ~$1.1B in the US alone through partner NS Pharma may prove conservative. Reiterate Outperform.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:57 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $77.85, showing a strong position within its recent range. The RSI at 55.56 indicates a neutral to slightly bullish sentiment, suggesting potential for upward movement. The stock is above both the 30-day MA (74.13) and the 50-day MA (70.28), reinforcing a bullish bias. Directional Bias: The recent high of $87.50 and low of $57.47 creates a favorable range for potential gains. The current price is closer to the high, indicating upward momentum. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close) - Stop Loss: $74.00 (to limit downside risk) - Take Profit Targets: 1. $82.00 (5% gain) 2. $85.00 (8.5% gain) 3. $91.00 (17% gain, targeting a significant return) This plan offers a structured approach to capitalize on the upward potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:32 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $77.85, showing a strong position within its recent range. The RSI at 55.56 indicates a neutral to slightly bullish sentiment, suggesting potential for upward movement. The stock is above both the 30-day MA (74.13) and the 50-day MA (70.28), reinforcing a bullish bias. Directional Bias: The recent high of $87.50 and low of $57.47 creates a favorable range for potential gains. The current price is closer to the high, indicating upward momentum. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close) - Stop Loss: $74.00 (to limit downside risk) - Take Profit Targets: 1. $82.00 (5% gain) 2. $85.00 (8.5% gain) 3. $91.00 (17% gain, targeting a significant return) This plan offers a structured approach to capitalize on the upward potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 2:59 PM
$PTCT Current Stock Price: $76.71 Contracts to trade: $75 PTCT Dec 19 2025 Call Entry: $2.58 Exit: $4.68 ROI: 81% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JasonCO
JasonCO Dec. 4 at 3:35 PM
$PTCT nice bounce from Wed lows
0 · Reply
Quantumup
Quantumup Dec. 3 at 8:15 PM
JonesTrading⬆️ $CAPR's PT to $51 from $29,⬆️PoS to 80%, and reiterated at a Buy rating. $EWTX $PTCT $SRPT Here's what JonesTrading had to say in its note to investors: https://x.com/Quantumup1/status/1996311057824903227?s=20
1 · Reply